Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease

During the past decade, transdermal delivery systems (TDS) have become increasingly important for treating neurologic and psychiatric disorders. The rivastigmine patch was the first patch to be approved to treat Alzheimer’s disease (AD). The 9.5 mg/24 h patch has equal efficacy to the capsules and r...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Wentrup, Andreas, Oertel, Wolfgang H, Dodel, Richard
Materialtyp: Artigo
Språk:Inglês
Publicerad: Dove Medical Press 2009
Ämnen:
Review
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2761169/
https://ncbi.nlm.nih.gov/pubmed/19920911
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk